The Latest Breaking News from AnaptysBio

Benzinga Pro data, AnaptysBio (NASDAQ:ANAB) reported Q1 sales of $970.00 thousand. Earnings fell to a loss of $36.26 million, resulting in a 11.42% decrease from last quarter.

AnaptysBio Inc (NASDAQ:ANAB) announced topline data from a Phase 1 trial of ANB032, an anti-BTLA agonist antibody.  Topline data demonstrated favorable safety, tolerability, and rapid and sustained pharmacokinetics and pharmacodynamic profile, supporting the advancement of ANB032 into subsequent patient trials. ANB032 was generally well-tolerated, and no dose-limiting toxicities were observed. The Company said…

AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne 

AnaptysBio (NASDAQ:ANAB) brought in sales totaling $1.01 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 388.12%, resulting in a loss of $32.54 million.